AM

Amicogen, Inc.

Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.

092040 | KO

Overview

Corporate Details

ISIN(s):
KR7092040005
LEI:
Country:
South Korea
Address:
경상남도 진주시 문산읍 월아산로950번길 14-10 아미코젠 문산 1공장, 진주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Amicogen, Inc. is an industrial biotechnology company founded in 2000 that specializes in the research, development, and production of special enzymes and other bio-new materials. Leveraging its core enzyme technology, the company provides solutions for the pharmaceutical and healthcare sectors. Its business areas include developing functional ingredients for health and nutrition through its KNUTRA brand, producing cell culture media, and offering Contract Development and Manufacturing Organization (CDMO) services for the bioprocess industry. Amicogen is focused on creating sustainable value for human health and the environment through continuous innovation and R&D.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-18 00:00
Share Issue/Capital Change
전환가액의조정 (제4회차)
Korean 10.6 KB
2025-09-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-20 00:00
Regulatory News Service
불성실공시법인지정 (공시변경)
Korean 6.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.3 MB
2025-08-11 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제6회차 CB)
Korean 5.6 KB
2025-08-01 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 49.8 KB
2025-07-30 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (대여금 청구-취하)
Korean 7.0 KB
2025-07-28 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 7.3 KB
2025-07-25 00:00
Regulatory News Service
불성실공시법인지정예고
Korean 4.9 KB
2025-07-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-25 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 12.1 KB
2025-05-23 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.9 MB

Automate Your Workflow. Get a real-time feed of all Amicogen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Amicogen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Amicogen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ORASURE TECHNOLOGIES INC Logo
Develops and distributes point-of-care diagnostic tests and sample collection devices.
United States of America
OSUR
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden
ORX
ORGANIGRAM GLOBAL INC. Logo
Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.
United States of America
OGI
Organon & Co. Logo
A global healthcare company focused on women's health, biosimilars, and established brands worldwide.
United States of America
OGN
Oric Pharmaceuticals, Inc. Logo
Developing therapies to overcome resistance in lung and prostate cancer.
United States of America
ORIC
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland
ORNAV
Oruka Therapeutics, Inc. Logo
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
United States of America
ORKA
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.